Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Laurus Labs Ltd. Share Price
Day's Range
Day's Range
Low
₹1,460.00
High
₹1,524.60
Price Summary
| Previous Close | ₹1,507.40 |
|---|---|
| Day's Range | ₹1,460.00 - ₹1,524.60 |
| Open | ₹1,468.10 |
| 52 Week Range | ₹775.15 - ₹1,555.00 |
| Volume | 20,35,031 |
| Market Cap | ₹0.08 |
| Previous Close | ₹1,503.20 |
|---|---|
| Day's Range | ₹1,459.75 - ₹1,524.00 |
| Open | ₹1,459.80 |
| 52 Week Range | ₹775.40 - ₹1,555.00 |
| Volume | 1,01,905 |
| Market Cap | ₹0.08 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 30,676.06 |
|---|---|
| Market Cap (₹ in Mn) | 0.08 |
| Dividend Yield(%) | 0.14 |
| Price/Earning (TTM) | 89.34 |
| TTM EPS (₹) | 16.45 |
| P/E Ratio | 60.25 |
| Book Value(₹) | 15.05 |
| PAT Margin (%) | 13.06 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 18.20 |
| Trade Value ( ₹ in Lacs) | 1,531.84 |
|---|---|
| Market Cap (₹ in Mn) | 0.08 |
| Dividend Yield(%) | 0.14 |
| Price/Earning (TTM) | 89.34 |
| TTM EPS (₹) | 16.45 |
| P/E Ratio | 60.25 |
| Book Value(₹) | 15.05 |
| PAT Margin (%) | 13.06 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 18.20 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 52169.8 | 16500.1 |
| Expenses | N/A | N/A |
| PBT | 5038.1 | 3302.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 3803.9 | 2519.0 |
About Laurus Labs Ltd.
| Founded | 2005 |
|---|---|
| NSE Symbol | LAURUSLABS |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,52,982.45 | 1,938.85 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,79,361.19 | 6,815.50 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,64,736.63 | 4,896.65 | 3,307.60 - 3,307.60 |
| Apollo Hospitals Enterprise Ltd. | 1,25,808.70 | 8,837.50 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,15,655.17 | 1,441.70 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,14,613.19 | 1,159.85 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,12,572.73 | 1,269.80 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,12,362.61 | 2,504.75 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,05,561.24 | 1,097.30 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,02,794.70 | 2,541.55 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Laurus Labs informs about AGM
Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Laurus Labs has informed that it enclosed the Notice convening the 21st Annual General Meeting (‘AGM’) of shareholders of the Company, scheduled to be held on Thursday, July 2, 2026 at 3.00 pm (IST) through Video Conferencing (‘VC’)/ through Other Audio-Visual Means (‘OAVM’). The Notice of 21st AGM is also available on the Company’s website at www.lauruslabs.com.
The above information is a part of company’s filings submitted to BSE.
Laurus Labs informs about newspaper advertisements
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Laurus Labs has informed that it enclosed copies of the newspaper advertisements pertaining to Notice to Shareholders with respect to, ‘Submission of TDS related documents for 2nd Interim Dividend for FY 2025-26’. The advertisements were published in ‘Business Standard’ (English) and ‘Prajasakti’ (Telugu) on May 07, 2026.
Laurus Labs informs about press release
Hikal informs about confirmation certificate
Pursuant to the provisions of Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, Hikal has informed that it enclosed confirmation certificate dated July 01, 2026, received from MUFG Intime India, Registrar and Share Transfer Agent (RTA) of the Company, for the quarter ended June 30, 2026.
The above information is a part of company’s filings submitted to BSE.
HealthCare Global Enterprises submits scrutinizer’s report and voting results
HealthCare Global Enterprises has informed that, pursuant to provisions of Section 110 of the Companies Act, 2013, read with Rule 22 of the Companies (Management and Administration) Rules, 2014, Regulation 44(3) of SEBI Listing Regulations, and further to its intimation to Stock Exchanges on June 08, 2026, the approval of members of the Company was sought by remote e-voting process in respect of the resolutions set out in the Postal Ballot Notice dated June 08, 2026. In this regard, it enclosed the following: (i) Voting Results in compliance with Regulation 44(3) of SEBI Listing Regulations; and (ii) Consolidated Report of the Scrutinizer dated July 09, 2026, issued by, V Sreedharan, Senior Partner, V Sreedharan and Associates, Company Secretaries, on the remote e-voting conducted through the Postal Ballot process, pursuant to the provisions of Section 110 of the Companies Act, 2013 read with Rule 22 of the Companies (Management and Administration) Rules, 2014. Detailed information in this regard in accordance with Regulation 30 read with SEBI Circulars SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and HO/49/14/14(7)2025- CFDPOD2/I/3762/2026 dated January 30, 2026, is annexed as Annexure-A. The above information is also available on the website of the Company and can be accessed at: https://www.hcgoncology.com/.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Laurus Labs Ltd. is ₹1,507.40 as of 2026-07-09.
The market capitalisation of Laurus Labs Ltd. is ₹79,403.18 as of 2026-07-08.
The 1-year return of Laurus Labs Ltd. is 729.10% as of 2026-07-09.
The P/E ratio of Laurus Labs Ltd. is 60.25 as of 2026-07-09.
The 52-week high and low of Laurus Labs Ltd. are ₹1,555.00 and ₹775.15, respectively, as of 2026-07-09.
People Also Ask
Laurus Labs Ltd. provides active pharmaceutical ingredients, generic formulations and contract‑development/manufacturing services, with strengths in antivirals, oncology and chronic therapies.
Laurus Labs Ltd. collaborates via API and formulation supply agreements and CDMO partnerships with global generic and branded pharma companies that serve hospitals worldwide.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
